Search Results Search Sort by RelevanceMost Recent Health Law Apr 2019 Regulating Nanomedicine at the Food and Drug Administration Jordan Paradise, JD Nanoscale products pose ethical, legal, and policy challenges to governing the use of products that integrate multiple mechanisms of therapeutic action. AMA J Ethics. 2019;21(4):E347-355. doi: 10.1001/amajethics.2019.347. Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care. Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Medicine and Society Oct 2019 How Should Decision Aids Be Used During Counseling to Help Patients Who Are “Genetically at Risk”? Natalie Evans, PhD, Suzanne Metselaar, PhD, Carla van El, PhD, Nina Hallowell, DPhil, MA, and Guy Widdershoven, PhD Prognostic uncertainty about risk creates demand for ongoing communication and facilitated reflection about goals and values. AMA J Ethics. 2019;21(10):E865-872. doi: 10.1001/amajethics.2019.865. Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936. Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021. Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036. Policy Forum Dec 2019 How Should Gene Editing Be Managed by Risk Managers? David Sine, D.Bioethics Little claims data exists upon which to make informed decisions about loss control or to draw upon when developing risk mitigation strategies. AMA J Ethics. 2019;21(12):E1059-1064. doi: 10.1001/amajethics.2019.1059. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600. Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Health Law Apr 2019 Regulating Nanomedicine at the Food and Drug Administration Jordan Paradise, JD Nanoscale products pose ethical, legal, and policy challenges to governing the use of products that integrate multiple mechanisms of therapeutic action. AMA J Ethics. 2019;21(4):E347-355. doi: 10.1001/amajethics.2019.347.
Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care.
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Medicine and Society Oct 2019 How Should Decision Aids Be Used During Counseling to Help Patients Who Are “Genetically at Risk”? Natalie Evans, PhD, Suzanne Metselaar, PhD, Carla van El, PhD, Nina Hallowell, DPhil, MA, and Guy Widdershoven, PhD Prognostic uncertainty about risk creates demand for ongoing communication and facilitated reflection about goals and values. AMA J Ethics. 2019;21(10):E865-872. doi: 10.1001/amajethics.2019.865.
Case and Commentary Nov 2019 In Experimental Hand Transplantation, Whose Views About Outcomes Should Matter Most? Andrea DiMartini, MD and Mary Amanda Dew, PhD Clinician-researchers deeply invested in data gathering are still obliged to respect a patient-subject’s right to stop being in research. AMA J Ethics. 2019;21(11):E936-942. doi: 10.1001/amajethics.2019.936.
Case and Commentary Dec 2019 How Should Physicians Respond When They Learn Patients Are Using Unapproved Gene Editing Interventions? Carolyn Riley Chapman, PhD, MS and Arthur L. Caplan, PhD Responding to patients violating US health commerce regulations can be critical when they buy and use unproven interventions. AMA J Ethics. 2019;21(12):E1021-1028. doi: 10.1001/amajethics.2019.1021.
Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036.
Policy Forum Dec 2019 How Should Gene Editing Be Managed by Risk Managers? David Sine, D.Bioethics Little claims data exists upon which to make informed decisions about loss control or to draw upon when developing risk mitigation strategies. AMA J Ethics. 2019;21(12):E1059-1064. doi: 10.1001/amajethics.2019.1059.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600.